🔈 Institut Curie's teams are at #ESMO26
Come and meet our experts at Institut Curie's booth to discuss the latest advances in #oncology, share ideas and explore new collaborations opportunities!
📍 Institut Curie - Booth #8042
#Oncsky #MedOnc @myesmo.bsky.social
Come and meet our experts at Institut Curie's booth to discuss the latest advances in #oncology, share ideas and explore new collaborations opportunities!
📍 Institut Curie - Booth #8042
#Oncsky #MedOnc @myesmo.bsky.social
October 24, 2026 at 9:14 AM
🔈 Institut Curie's teams are at #ESMO26
Come and meet our experts at Institut Curie's booth to discuss the latest advances in #oncology, share ideas and explore new collaborations opportunities!
📍 Institut Curie - Booth #8042
#Oncsky #MedOnc @myesmo.bsky.social
Come and meet our experts at Institut Curie's booth to discuss the latest advances in #oncology, share ideas and explore new collaborations opportunities!
📍 Institut Curie - Booth #8042
#Oncsky #MedOnc @myesmo.bsky.social
24h in oncology: 459 new papers.
42 in a top-5% journal (1 in an elite journal) — signal over noise.
You read what matters, not all of PubMed.
#Oncology #MedOnc #MedSky #EvidenceBasedMedicine
42 in a top-5% journal (1 in an elite journal) — signal over noise.
You read what matters, not all of PubMed.
#Oncology #MedOnc #MedSky #EvidenceBasedMedicine
September 9, 2026 at 8:36 PM
24h in oncology: 459 new papers.
42 in a top-5% journal (1 in an elite journal) — signal over noise.
You read what matters, not all of PubMed.
#Oncology #MedOnc #MedSky #EvidenceBasedMedicine
42 in a top-5% journal (1 in an elite journal) — signal over noise.
You read what matters, not all of PubMed.
#Oncology #MedOnc #MedSky #EvidenceBasedMedicine
📊 SURVEY: The YAU #ProstateCancer Working Group in collaboration with the ESTRO #Urology Focus Group need your insights on bone health management for patients receiving ADT. Help us map global clinical challenges.
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
August 31, 2026 at 3:37 PM
📊 SURVEY: The YAU #ProstateCancer Working Group in collaboration with the ESTRO #Urology Focus Group need your insights on bone health management for patients receiving ADT. Help us map global clinical challenges.
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
Applications are due TOMORROW/Sept 1st for the following committee leadership openings: MedOnc Vice Chair/Non-Colorectal GI Cancer Subcommittee; Chair/Intl Members Subcommittee; Vice Chair/Early Career Mentorship Subcommittee
Read More & How to Apply ➡️https://ow.ly/hxCU50ZrsUP
Read More & How to Apply ➡️https://ow.ly/hxCU50ZrsUP
August 31, 2026 at 1:00 PM
Applications are due TOMORROW/Sept 1st for the following committee leadership openings: MedOnc Vice Chair/Non-Colorectal GI Cancer Subcommittee; Chair/Intl Members Subcommittee; Vice Chair/Early Career Mentorship Subcommittee
Read More & How to Apply ➡️https://ow.ly/hxCU50ZrsUP
Read More & How to Apply ➡️https://ow.ly/hxCU50ZrsUP
📊 SURVEY: The YAU #ProstateCancer Working Group in collaboration with the ESTRO #Urology Focus Group need your insights on bone health management for patients receiving ADT. Help us map global clinical challenges.
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
August 18, 2026 at 2:06 PM
📊 SURVEY: The YAU #ProstateCancer Working Group in collaboration with the ESTRO #Urology Focus Group need your insights on bone health management for patients receiving ADT. Help us map global clinical challenges.
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
📅 Closes Sept 2026
👉https://bit.ly/3SBNqer #RadOnc #MedOnc
Understanding Rare Alterations in #NSCLC 🫁
WATCH HERE 👉 cor2ed.com/understandin...
In this video by COR2ED, Dr Joshua Sabari, a MedOnc specialising in rare alterations of NSCLC, and Debra Montague give 2 different perspectives on optimising care for patients with NSCLC driven by rare alteration
WATCH HERE 👉 cor2ed.com/understandin...
In this video by COR2ED, Dr Joshua Sabari, a MedOnc specialising in rare alterations of NSCLC, and Debra Montague give 2 different perspectives on optimising care for patients with NSCLC driven by rare alteration
January 5, 2026 at 10:00 AM
Understanding Rare Alterations in #NSCLC 🫁
WATCH HERE 👉 cor2ed.com/understandin...
In this video by COR2ED, Dr Joshua Sabari, a MedOnc specialising in rare alterations of NSCLC, and Debra Montague give 2 different perspectives on optimising care for patients with NSCLC driven by rare alteration
WATCH HERE 👉 cor2ed.com/understandin...
In this video by COR2ED, Dr Joshua Sabari, a MedOnc specialising in rare alterations of NSCLC, and Debra Montague give 2 different perspectives on optimising care for patients with NSCLC driven by rare alteration
Congratulations to Dr. Omnia Mohamed Korani, MedOnc at NCI Egypt🇪🇬
Recipient of an @OncoAlert 🚨Catalyst fellowship Her project focuses on Investigating Awareness of Genetic Predisposition to #BreastCancer
@elisabettabonzano.bsky.social
@elisaagostinetto.bsky.social
@realbowtiedoc.bsky.social
Recipient of an @OncoAlert 🚨Catalyst fellowship Her project focuses on Investigating Awareness of Genetic Predisposition to #BreastCancer
@elisabettabonzano.bsky.social
@elisaagostinetto.bsky.social
@realbowtiedoc.bsky.social
November 19, 2024 at 1:41 PM
Congratulations to Dr. Omnia Mohamed Korani, MedOnc at NCI Egypt🇪🇬
Recipient of an @OncoAlert 🚨Catalyst fellowship Her project focuses on Investigating Awareness of Genetic Predisposition to #BreastCancer
@elisabettabonzano.bsky.social
@elisaagostinetto.bsky.social
@realbowtiedoc.bsky.social
Recipient of an @OncoAlert 🚨Catalyst fellowship Her project focuses on Investigating Awareness of Genetic Predisposition to #BreastCancer
@elisabettabonzano.bsky.social
@elisaagostinetto.bsky.social
@realbowtiedoc.bsky.social
@joshtpm.bsky.social from @talkingpointsmemo.com is looking for med schools who received requests for admissions records from DoJ. His signal and protonmail accounts are in the original post.
#AcademicSky #MedSky #MedEd #PedSky #MedOnc #EMSky
#AcademicSky #MedSky #MedEd #PedSky #MedOnc #EMSky
Question: I'm looking for examples of Medical Schools which may just have received a letter from the Justice Department demanding detailed records of the School's admissions going back 5 years. If you have information: Signal joshtpm.99 or joshtpm at protonmail dot com. All comms confidential.
April 25, 2025 at 11:57 PM
@joshtpm.bsky.social from @talkingpointsmemo.com is looking for med schools who received requests for admissions records from DoJ. His signal and protonmail accounts are in the original post.
#AcademicSky #MedSky #MedEd #PedSky #MedOnc #EMSky
#AcademicSky #MedSky #MedEd #PedSky #MedOnc #EMSky
#ESMO25 | New insights from the SOHO-01 study presented by Prof. NIcolas Girard @institutcurie.bsky.social:
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
October 19, 2025 at 1:13 PM
#ESMO25 | New insights from the SOHO-01 study presented by Prof. NIcolas Girard @institutcurie.bsky.social:
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
#ESMO25 | Uveal melanoma: positive results of the phase 2 PLUME clinical trial, presented by Dr. Manuel Rodrigues @institutcurie.bsky.social (efficacy and tolerability of immunotherapy anti-PD-1 + targeted treatment)
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
October 18, 2025 at 4:56 PM
#ESMO25 | Uveal melanoma: positive results of the phase 2 PLUME clinical trial, presented by Dr. Manuel Rodrigues @institutcurie.bsky.social (efficacy and tolerability of immunotherapy anti-PD-1 + targeted treatment)
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
#ESMO25 | Promising real-world data from the french multicenter LARENA study presented by Dr Diana Bello-Roufai @institutcurie.bsky.social, show that adapting pembrolizumab-lenvatinib dosing in metastatic endometrial cancer reduces toxicity without compromising efficacy.
#medonc
#medonc
October 18, 2025 at 11:50 AM
#ESMO25 | Promising real-world data from the french multicenter LARENA study presented by Dr Diana Bello-Roufai @institutcurie.bsky.social, show that adapting pembrolizumab-lenvatinib dosing in metastatic endometrial cancer reduces toxicity without compromising efficacy.
#medonc
#medonc
Good communication matters—especially when ending a financial program for life-saving medication. My latest blog post looks at how companies can deliver clearer, more empathetic messages in sensitive situations like this. 👇
#CanSky #OncoSky #MedSky #MedOnc #Pharmaceutical #EffectiveCommunications
#CanSky #OncoSky #MedSky #MedOnc #Pharmaceutical #EffectiveCommunications
Dear Pharmaceutical,
I am reaching out regarding your recent communication to Canadian cancer patients about the discontinuation of your IBRANCE co-pay program. While I am not personally affected by this change, many o…
kwadrans.ca
March 17, 2025 at 7:58 PM
Good communication matters—especially when ending a financial program for life-saving medication. My latest blog post looks at how companies can deliver clearer, more empathetic messages in sensitive situations like this. 👇
#CanSky #OncoSky #MedSky #MedOnc #Pharmaceutical #EffectiveCommunications
#CanSky #OncoSky #MedSky #MedOnc #Pharmaceutical #EffectiveCommunications
The gonorrhoea vaccine is an incredible breakthrough. It could also be a terrible missed opportunity | Benjamin Weil
The gonorrhoea vaccine is an incredible breakthrough. It could also be a terrible missed opportunity | Benjamin Weil
Vaccines that work need systems that work. Britain’s starved services must be supported to reach those most at risk, says researcher Benjamin Weil
www.theguardian.com
May 28, 2025 at 4:03 PM
#TobRegSky #PedSky #MedSky #addictionsci #policysky #neuroskyence #cansky #oncsky #cancer #cancercare #oncology #cancerawareness #health #medicine #MedEd #MedOnc#polisky #episky🛟
75 years this week since evidence confirming that smoking is lethal with Wynder & Graham’s landmark May 27, 1950 JAMA paper “Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma” then Doll & Hill’s historic September 30, 1950 BMJ “Smoking and carcinoma of the lung”.
May 25, 2025 at 11:21 PM
Finally made the move! Send any #medonc and #medtwitter starter packs my way 🙏🏻
November 18, 2024 at 7:56 AM
Finally made the move! Send any #medonc and #medtwitter starter packs my way 🙏🏻
Come on @ASCO, it’s time to speak out and condemn what is happening at the #CDC and department of health and human services under RFK Jr. It’s not just US public health & scientific research at risk here - there are global consequences & implications. #medtwitter #medonc #radonc #ASCO
August 29, 2025 at 7:09 AM
Come on @ASCO, it’s time to speak out and condemn what is happening at the #CDC and department of health and human services under RFK Jr. It’s not just US public health & scientific research at risk here - there are global consequences & implications. #medtwitter #medonc #radonc #ASCO
Great to see @drsanjaypopat.bsky.social on #BlueSky. An absolutely essential follow if you have an interest in lung/thoracic cancers. #medonc #radonc #lcsm #mesothelioma #thymoma #MedSky
https://bsky.app/profile/drsanj…
December 1, 2024 at 1:48 PM
Great to see @drsanjaypopat.bsky.social on #BlueSky. An absolutely essential follow if you have an interest in lung/thoracic cancers. #medonc #radonc #lcsm #mesothelioma #thymoma #MedSky
Management of Patients with Advanced Prostate Cancer. APCCC 2024 #PCSM #medonc #radonc #MedSky
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that …
www.sciencedirect.com
November 19, 2024 at 12:55 PM
Management of Patients with Advanced Prostate Cancer. APCCC 2024 #PCSM #medonc #radonc #MedSky
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Hey #MedSky, let’s get talking about BlueSky with our colleagues at work and at our medical conferences. Let’s rebuild an educational and scientific community on here.
As a steering committee member of #BTOG & UK SABR Consortium, I’ve already added to our agenda for next meetings #radonc #medonc
As a steering committee member of #BTOG & UK SABR Consortium, I’ve already added to our agenda for next meetings #radonc #medonc
November 18, 2024 at 2:42 PM
From Kyoto University Student to Full Professor - Please Invite Bishal Gyawali Back to Japan
@ptarantinomd.bsky.social
oncodaily.com/voices/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@ptarantinomd.bsky.social
oncodaily.com/voices/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Paolo Tarantino։ From Kyoto University Student to Full Professor: Please Invite Bishal Gyawali Back to Japan - OncoDaily
Paolo Tarantino։ From Kyoto University Student to Full Professor: Please Invite Bishal Gyawali Back to Japan / Bishal Gyawali, cancer, Kazuki Nozawa,
oncodaily.com
May 27, 2026 at 6:33 PM
From Kyoto University Student to Full Professor - Please Invite Bishal Gyawali Back to Japan
@ptarantinomd.bsky.social
oncodaily.com/voices/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@ptarantinomd.bsky.social
oncodaily.com/voices/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Lung Cancer Abstracts I’ll Be Watching Closely at ASCO26 - Eric Singhi
@lungoncdoc.bsky.social
oncodaily.com/voices/eric-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@lungoncdoc.bsky.social
oncodaily.com/voices/eric-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Eric Singhi: Lung Cancer Abstracts I’ll Be Watching Closely at ASCO26 - OncoDaily
Eric Singhi: Lung Cancer Abstracts I’ll Be Watching Closely at ASCO26 / ASCO26, cancer, Eric Singhi, Lung cancer, OncoDaily, Oncology
oncodaily.com
May 27, 2026 at 5:35 PM
Lung Cancer Abstracts I’ll Be Watching Closely at ASCO26 - Eric Singhi
@lungoncdoc.bsky.social
oncodaily.com/voices/eric-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@lungoncdoc.bsky.social
oncodaily.com/voices/eric-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
From Community Oncology to the ASCO Stage - Matthew Kurian
@matthewkurianmd.bsky.social @ascocancer.bsky.social @drteplinsky.bsky.social
oncodaily.com/voices/matth...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@matthewkurianmd.bsky.social @ascocancer.bsky.social @drteplinsky.bsky.social
oncodaily.com/voices/matth...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Matthew Kurian: From Community Oncology to the ASCO Stage - OncoDaily
Matthew Kurian: From Community Oncology to the ASCO Stage / ASCO, cancer, Daniel Flora, Debra Patt, Douglas Flora, Eleonora Teplinsky, Matthew Kurian,
oncodaily.com
May 27, 2026 at 5:11 PM
From Community Oncology to the ASCO Stage - Matthew Kurian
@matthewkurianmd.bsky.social @ascocancer.bsky.social @drteplinsky.bsky.social
oncodaily.com/voices/matth...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@matthewkurianmd.bsky.social @ascocancer.bsky.social @drteplinsky.bsky.social
oncodaily.com/voices/matth...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews